Oxford Biomedica plc OXOA.F Stock
Oxford Biomedica plc Price Chart
Oxford Biomedica plc OXOA.F Financial and Trading Overview
| Oxford Biomedica plc stock price | 3.84 EUR |
| Previous Close | 5.35 EUR |
| Open | 5.3 EUR |
| Bid | 5.25 EUR x 0 |
| Ask | 5.8 EUR x 0 |
| Day's Range | 5.3 - 5.3 EUR |
| 52 Week Range | 3.3 - 6.65 EUR |
| Volume | 7 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 523.43M EUR |
| Beta (5Y Monthly) | 0.922222 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
OXOA.F Valuation Measures
| Enterprise Value | 519.53M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3.7391074 |
| Price/Book (mrq) | 2.4929447 |
| Enterprise Value/Revenue | 3.711 |
| Enterprise Value/EBITDA | -20.755 |
Trading Information
Oxford Biomedica plc Stock Price History
| Beta (5Y Monthly) | 0.922222 |
| 52-Week Change | 10.99% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.65 EUR |
| 52 Week Low | 3.3 EUR |
| 50-Day Moving Average | 4.84 EUR |
| 200-Day Moving Average | 4.66 EUR |
OXOA.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 96.52M |
| Float | 69.74M |
| Short Ratio | N/A |
| % Held by Insiders | 8.56% |
| % Held by Institutions | 61.13% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:50 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -27.97% |
| Operating Margin (ttm) | -33.18% |
| Gross Margin | 49.41% |
| EBITDA Margin | -17.88% |
Management Effectiveness
| Return on Assets (ttm) | -8.32% |
| Return on Equity (ttm) | -21.32% |
Income Statement
| Revenue (ttm) | 139.99M EUR |
| Revenue Per Share (ttm) | 1.48 EUR |
| Quarterly Revenue Growth (yoy) | 23.40% |
| Gross Profit (ttm) | N/A |
| EBITDA | -25031000 EUR |
| Net Income Avi to Common (ttm) | -39157000 EUR |
| Diluted EPS (ttm) | -0.49 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 141.31M EUR |
| Total Cash Per Share (mrq) | 1.47 EUR |
| Total Debt (mrq) | 114.28M EUR |
| Total Debt/Equity (mrq) | 48.39 EUR |
| Current Ratio (mrq) | 3.612 |
| Book Value Per Share (mrq) | 2.126 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -12615000 EUR |
| Levered Free Cash Flow (ttm) | -12800250 EUR |
Profile of Oxford Biomedica plc
| Country | Germany |
| State | N/A |
| City | Oxford |
| Address | Windrush Court |
| ZIP | OX4 6LT |
| Phone | 44 1865 783 000 |
| Website | https://www.oxb.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 894 |
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological malignancies and tumours; and OXB-401 that is in pre-clinical stage for the treatment of liver indication; as well as OXB-40X, OXB-40Y, and OXB-40Z, which are in pre-clinical stage for liver indication. The company has collaborations with Boehringer Ingelheim, Immatics, Arcellx, Orchard, and Beam Therapeutics; an agreement with Homology Medicines; license and clinical supply agreement with Juno Therapeutics, Inc.; and master services and development agreement with AstraZeneca UK Ltd and Serum Life Sciences Ltd. The company also has a strategic collaboration with Kite Pharma to develop and commercialize CART-ddBCMA, a lead late-stage product candidate. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Q&A For Oxford Biomedica plc Stock
What is a current OXOA.F stock price?
Oxford Biomedica plc OXOA.F stock price today per share is 3.84 EUR.
How to purchase Oxford Biomedica plc stock?
You can buy OXOA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Oxford Biomedica plc?
The stock symbol or ticker of Oxford Biomedica plc is OXOA.F.
Which industry does the Oxford Biomedica plc company belong to?
The Oxford Biomedica plc industry is Biotechnology.
How many shares does Oxford Biomedica plc have in circulation?
The max supply of Oxford Biomedica plc shares is 103.68M.
What is Oxford Biomedica plc Price to Earnings Ratio (PE Ratio)?
Oxford Biomedica plc PE Ratio is now.
What was Oxford Biomedica plc earnings per share over the trailing 12 months (TTM)?
Oxford Biomedica plc EPS is -1.9 EUR over the trailing 12 months.
Which sector does the Oxford Biomedica plc company belong to?
The Oxford Biomedica plc sector is Healthcare.